Bayer Pharma Aktiengesellschaft

Berlin, Germany

Bayer Pharma Aktiengesellschaft

Berlin, Germany
SEARCH FILTERS
Time filter
Source Type

Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-04-05

The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula(I)as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-05-17

A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of:a) freezing droplets of a solution comprising factor VIII to form pellets;b) freeze-drying the pellets;wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-05-31

The present invention relates to amino-substituted isoxazoles of general formula (I) : in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-05-31

The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-03-15

Disclosed herein is a method for monitoring the concentration of at least one kind of contaminant in a fluid stream, comprising the steps of providing at least two unit operations, providing a fluid stream, which passes said at least two unit operations in a flow path, sampling the fluid stream in a predetermined valid manner, determining the contaminant concentration in the sample in order to monitor the contaminant concentration in the fluid stream, wherein the method is carried out under continuous, closed and pathogen-reduced conditions.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-03-22

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 29 kDa polypeptide named C4.4a , which is over expressed in tumors. C4.4a has a high abundance in metastases of several cancer types. The antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of C4.4a in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-01-25

The present invention relates to compounds of general formula (I) :^(1), R^(2), R^(3), R^(4), R^(6), R^(7), R^(8), R^(9), R^(10), R^(11), R^(12), R^(13) and X are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-02-02

The present application relates to novel 2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide derivatives (thienouracil-carboxamides), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for the preparation of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiovascular disorders.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-02-08

The invention relates to novel 2,5-disubstituted cyclopentane carboxylic acid derivatives, to methods for the preparation thereof, to the use thereof alone or in combination for the treatment and/or prevention of disorders, and to the use thereof for producing medicaments for the treatment and/or prevention of disorders, especially for treatment and/or prevention of diseases of the respiratory tract, lung and of the cardiovascular system.


Patent
Bayer Pharma Aktiengesellschaft | Date: 2017-02-08

The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Loading Bayer Pharma Aktiengesellschaft collaborators
Loading Bayer Pharma Aktiengesellschaft collaborators